Curetis Announces the Exercise of the Over-Allotment Option
(Thomson Reuters ONE) -
Curetis AG /
Curetis Announces the Exercise of the Over-Allotment Option
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH
AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS
ANNOUNCEMENT.
Holzgerlingen, Germany, December 3, 2015 -- Curetis N.V. (the "Company" and,
together with Curetis AG, "Curetis"), a developer of next-level molecular
diagnostic solutions, announces today the partial exercise of the Over-allotment
Option (as defined below) by RBC Capital Markets, acting as the sole global
coordinator on behalf of RBC Capital Markets, Bank Degroof Petercam and ICF Bank
AG (the "Underwriters"), and the end of the stabilisation period in relation to
its initial public offering on Euronext in Amsterdam and Euronext in Brussels
(the "IPO" or the "Offering").
As part of its IPO and as set forth in the prospectus dated October 27, 2015,
Curetis granted the sole global coordinator, on behalf of the Underwriters, an
option to purchase up to 600,000 additional shares at the offer price of EUR
10.00, which was exercisable for a period of 30 calendar days following the
first day of listing and trading of Curetis' shares on Euronext in Amsterdam and
Euronext in Brussels (i.e. November 11, 2015) (the "Over-allotment Option").
On December 3, 2015, the sole global coordinator, on behalf of the Underwriters,
exercised the Over-allotment Option for 431,033 shares, raising additional gross
proceeds of EUR 4,310,330 for Curetis.
Including the exercise of the Over-allotment Option, the total size of the
Offering was 4,431,033 ordinary shares, representing 28.5% of the 15,538,411
ordinary shares of the Company, upon settlement.
The new shares will be listed on Euronext in Amsterdam and Euronext in Brussels
and will be issued on or about December 7, 2015, and rank pari passu with the
existing shares.
Details of the stabilisation activity carried out by RBC Capital Markets, acting
as the stabilisation manager, are available in appendix A.
###
Contact details
Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com
www.curetis.com - www.unyvero.com
Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
About Curetis AG
Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on
the development and commercialization of reliable, fast and cost-effective
products for diagnosing severe infectious diseases. The diagnostic solutions of
Curetis AG enable rapid multi-parameter pathogen and antibiotic resistance
marker detection in only a few hours, a process that today can take up to days
or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million. The company
is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed
collaboration agreements with Heraeus Medical and Cempra Inc. as well as several
international distribution agreements covering many countries across Europe, the
Middle East and Asia.
For further information, please visit www.curetis.com.
Important legal information
These materials are for informational purposes only and are not intended to
constitute, and should not be construed as, an offer to sell or subscribe for,
or the announcement of a forthcoming offer to sell or subscribe for, or a
solicitation of any offer to buy or subscribe for, or the announcement of a
forthcoming solicitation of any offer to buy or subscribe for, ordinary shares
in the share capital of the Company (the "Shares") in the United States,
Australia, Canada, Japan, South Africa or in any other jurisdiction to whom or
in which such offer or solicitation is unlawful and the distribution of this
communication in jurisdictions may be similarly restricted. Persons into whose
possession this communication comes should inform themselves about and observe
any such restrictions. Any failure to comply with these restrictions may
constitute a violation of the security laws of any such jurisdiction.
The Shares have not been and will not be registered under the U.S. Securities
Act of 1933, as amended (the "Securities Act") and may not be offered or sold
within the United States absent registration or an exemption from the
registration requirements under the Securities Act. The Company does not intend
to register any portion of the offering in the United States or to conduct a
public offering of Shares in the United States. The securities referred to
herein may not be offered or sold in Australia, Canada, Japan, South Africa or
to, or for the account or benefit of, any national, resident or citizen of
Australia, Canada, Japan or South Africa.
The Company has not authorised any offer to the public of Shares in any Member
State of the European Economic Area, except in the Federal Republic of Germany
and the Netherlands. With respect to any Member State of the European Economic
Area which has implemented the Prospectus Directive other than the Netherlands
and Germany (each a "Relevant Member State"), no action has been undertaken or
will be undertaken to make an offer to the public of Shares requiring
publication of a prospectus in any Relevant Member State. As a result, the
Shares may only be offered in Relevant Member States:
(i) to any legal entity which is a "qualified investor" as defined in the
Prospectus Directive; or
(ii) in any other circumstances falling within Article 3(2) of the Prospectus
Directive.
For the purpose of this paragraph, the expression "offer of securities to the
public" means the communication in any form and by any means of sufficient
information on the terms of the offer and the Shares to be offered so as to
enable the investor to decide to exercise, purchase or subscribe for the Shares,
as the same may be varied in that Member State by any measure implementing the
Prospectus Directive in that Member State and the expression "Prospectus
Directive" means Directive 2003/71/EC (as amended, including by Directive
2010/73/EU), and includes any relevant implementing measure in the Relevant
Member State.
In the United Kingdom, this document and any other materials in relation to the
Shares is only being distributed to, and is only directed at, and any investment
or investment activity to which this document relates is available only to, and
will be engaged in only with, "qualified investors" (as defined in section
86(7) of the Financial Services and Markets Act 2000) and who are (i) persons
having professional experience in matters relating to investments who fall
within the definition of "investment professionals" in Article 19(5) of the
Financial Services and Markets Act 2000 ("Financial Promotion") Order 2005 (the
"Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d)
of the Order (all such persons together being referred to as "relevant
persons"). This communication is directed only at relevant persons. Persons who
are not relevant persons should not take any action on the basis of this
document and should not act or rely on it. Any investment activity to which this
communication relates will only be available to and will only be engaged with,
relevant persons. No action has been taken by the Company that would permit an
offer of Shares or the possession or distribution of these materials or any
other offering or publicity material relating to such Shares in any
jurisdiction, except for the Republic of Germany and the Netherlands, where
action for that purpose is required.
This announcement is not an advertisement within the meaning of the Prospectus
Directive and does not constitute a prospectus. An offer to acquire Shares is
made, and any investor should make his investment, solely on the basis of
information that is contained in the prospectus made generally available in
connection with this offering. Copies of the prospectus may be obtained through
the website of the Company.
This document may contain forward-looking statements. These statements are based
on the current views, expectations and assumptions of the management of the
Company and involve known and unknown risks and uncertainties that could cause
actual results, performance or events to differ materially from those expressed
or implied in such statements. You can identify forward-looking statements by
terms such as "believe", "anticipate", "expect", "estimate", "may", "could",
"should", "would", "will", "intend", "plan", the negative of such terms or other
similar expressions. Actual results, performance or events may differ materially
from those described in such statements due to, among other things, changes in
the general economic and competitive environment, risks associated with capital
markets, currency exchange rate fluctuations and competition from other
companies, changes in international and national laws and regulations, rapid
technological and market change in the industries the Company operates in, as
well as many other risks specifically related to the Company and its
operations.. The Company does not assume any obligations to update any forward-
looking statements.
Neither these materials nor any copy of it may be taken or transmitted, directly
or indirectly, into the United States, Australia, Canada, Japan or South Africa.
These materials do not constitute or form part of any offer or invitation to
sell, or any solicitation of any offer to purchase or subscribe nor shall it (or
any part of it) or the fact of its distribution, form the basis of, or be relied
on in connection with, any contract therefore. The offer and the distribution of
these materials and other information in connection with the listing and offer
in certain jurisdictions may be restricted by law.
The Underwriters are acting exclusively for the Company and no one else in
connection with the Offering and will not regard any other person as their
respective client in relation to the Offering and will not be responsible to
anyone other than the Company for providing the protections afforded to their
respective client or for giving advice in relation to the Offering or the
contents of this announcement or any transaction, arrangement or other matter
referred to herein.
None of the Underwriters or any of their respective subsidiary undertakings,
affiliates or any of their respective directors, officers, employees, advisers,
agents, alliance partners or any other entity or person accepts any
responsibility or liability whatsoever for, or makes any representation,
warranty or undertaking, express or implied, as to the truth, accuracy,
completeness or fairness of the information or opinions in this announcement (or
whether any information has been omitted from the announcement) or any other
information relating to the Company, its subsidiaries or associated companies,
whether written, oral or in a visual or electronic form, and howsoever
transmitted or made available or for any loss howsoever arising from any use of
this announcement or its contents or otherwise arising in connection therewith.
Appendix A
+------------------------------+-------------------------------------------+
| Date of stabilisation trades | Price range of stabilisation trades (EUR) |
| | |
+------------------------------+-------------------------------------------+
| 11 November 2015 | ?10 |
+------------------------------+-------------------------------------------+
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Curetis AG via GlobeNewswire
[HUG#1971191]
Unternehmensinformation / Kurzprofil:
Datum: 03.12.2015 - 13:26 Uhr
Sprache: Deutsch
News-ID 437403
Anzahl Zeichen: 14228
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 355 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis Announces the Exercise of the Over-Allotment Option"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
